Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney: Cardiovascular Diabetology

D. Giugliano; L. De Nicola; M.I. Maiorino; G. Bellastella; C. Garofalo; P. Chiodini; A. Ceriello; K. Esposito

doi:10.1186/s12933-020-01010-x

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney: Cardiovascular Diabetology

D. Giugliano, L. De Nicola, M.I. Maiorino, G. Bellastella, C. Garofalo, P. Chiodini, A. Ceriello, K. Esposito

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. © 2020 The Author(s).

Original language	English
Journal	Cardiovasc. Diabetol.
Volume	19
Issue number	1
DOIs	https://doi.org/10.1186/s12933-020-01010-x
Publication status	Published - 2020

Keywords

Diabetic kidney disease
MACE
SGLT-2 inhibitors
Statin therapy
Type 2 diabetes
hydroxymethylglutaryl coenzyme A reductase inhibitor
placebo
renin inhibitor
sodium glucose cotransporter 2 inhibitor
albuminuria
cardiovascular disease
cardiovascular response
cardiovascular risk
diabetic nephropathy
disease association
disease severity
drug efficacy
estimated glomerular filtration rate
high risk population
human
kidney function
meta analysis
non insulin dependent diabetes mellitus
outcome assessment
renal protection
Review
risk reduction
adverse event
chronic kidney failure
clinical trial (topic)
drug effect
kidney
pathophysiology
protection
risk assessment
risk factor
treatment outcome
Cardiovascular Diseases
Clinical Trials as Topic
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Kidney
Protective Factors
Renal Insufficiency, Chronic
Risk Assessment
Risk Factors
Sodium-Glucose Transporter 2 Inhibitors
Treatment Outcome

Access to Document

10.1186/s12933-020-01010-x

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082055076&doi=10.1186%2fs12933-020-01010-x&partnerID=40&md5=041c8f6fac17811b7fcc395887b2dff5

Fingerprint Dive into the research topics of 'Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney: Cardiovascular Diabetology'. Together they form a unique fingerprint.

Cite this

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney : Cardiovascular Diabetology. / Giugliano, D.; De Nicola, L.; Maiorino, M.I.; Bellastella, G.; Garofalo, C.; Chiodini, P.; Ceriello, A.; Esposito, K.

In: Cardiovasc. Diabetol., Vol. 19, No. 1, 2020.

Research output: Contribution to journal › Article › peer-review

@article{2e61cf75e32f452b863ba03b5476a798,

title = "Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney: Cardiovascular Diabetology",

abstract = "Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. {\textcopyright} 2020 The Author(s).",

keywords = "Diabetic kidney disease, MACE, SGLT-2 inhibitors, Statin therapy, Type 2 diabetes, hydroxymethylglutaryl coenzyme A reductase inhibitor, placebo, renin inhibitor, sodium glucose cotransporter 2 inhibitor, albuminuria, cardiovascular disease, cardiovascular response, cardiovascular risk, diabetic nephropathy, disease association, disease severity, drug efficacy, estimated glomerular filtration rate, high risk population, human, kidney function, meta analysis, non insulin dependent diabetes mellitus, outcome assessment, renal protection, Review, risk reduction, adverse event, chronic kidney failure, clinical trial (topic), drug effect, kidney, pathophysiology, protection, risk assessment, risk factor, treatment outcome, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kidney, Protective Factors, Renal Insufficiency, Chronic, Risk Assessment, Risk Factors, Sodium-Glucose Transporter 2 Inhibitors, Treatment Outcome",

author = "D. Giugliano and {De Nicola}, L. and M.I. Maiorino and G. Bellastella and C. Garofalo and P. Chiodini and A. Ceriello and K. Esposito",

note = "Cited By :4 Export Date: 1 March 2021 CODEN: CDAIA Correspondence Address: Giugliano, D.; Division of Endocrinology and Metabolic Diseases, Italy; email: dario.giugliano@unicampania.it",

year = "2020",

doi = "10.1186/s12933-020-01010-x",

language = "English",

volume = "19",

journal = "Cardiovasc. Diabetol.",

issn = "1475-2840",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: The role of kidney

T2 - Cardiovascular Diabetology

AU - Giugliano, D.

AU - De Nicola, L.

AU - Maiorino, M.I.

AU - Bellastella, G.

AU - Garofalo, C.

AU - Chiodini, P.

AU - Ceriello, A.

AU - Esposito, K.

N1 - Cited By :4 Export Date: 1 March 2021 CODEN: CDAIA Correspondence Address: Giugliano, D.; Division of Endocrinology and Metabolic Diseases, Italy; email: dario.giugliano@unicampania.it

PY - 2020

Y1 - 2020

N2 - Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. © 2020 The Author(s).

AB - Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy, this SGLT-2 inhibitors effect is unique because, at variance with other components of cardiorenal protection, MACE prevention does not appear to be a class effect. Here, we present meta-analysis of the four key CVOTs indicating a major role of renal function in determining the extent of MACE prevention, with the benefit increasing in more severe kidney disease, that is, a high-risk condition where effectiveness of the traditional approach with statins is reduced. © 2020 The Author(s).

KW - Diabetic kidney disease

KW - MACE

KW - SGLT-2 inhibitors

KW - Statin therapy

KW - Type 2 diabetes

KW - hydroxymethylglutaryl coenzyme A reductase inhibitor

KW - placebo

KW - renin inhibitor

KW - sodium glucose cotransporter 2 inhibitor

KW - albuminuria

KW - cardiovascular disease

KW - cardiovascular response

KW - cardiovascular risk

KW - diabetic nephropathy

KW - disease association

KW - disease severity

KW - drug efficacy

KW - estimated glomerular filtration rate

KW - high risk population

KW - human

KW - kidney function

KW - meta analysis

KW - non insulin dependent diabetes mellitus

KW - outcome assessment

KW - renal protection

KW - Review

KW - risk reduction

KW - adverse event

KW - chronic kidney failure

KW - clinical trial (topic)

KW - drug effect

KW - kidney

KW - pathophysiology

KW - protection

KW - risk assessment

KW - risk factor

KW - treatment outcome

KW - Cardiovascular Diseases

KW - Clinical Trials as Topic

KW - Diabetes Mellitus, Type 2

KW - Diabetic Nephropathies

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors

KW - Kidney

KW - Protective Factors

KW - Renal Insufficiency, Chronic

KW - Risk Assessment

KW - Risk Factors

KW - Sodium-Glucose Transporter 2 Inhibitors

KW - Treatment Outcome

U2 - 10.1186/s12933-020-01010-x

DO - 10.1186/s12933-020-01010-x

M3 - Article

VL - 19

JO - Cardiovasc. Diabetol.

JF - Cardiovasc. Diabetol.

SN - 1475-2840

IS - 1

ER -